Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Engineered extracellular vesicles for combinatorial TNBC therapy: SR-SIM-guided design achieves substantial drug dosage reduction

Molecular Therapy(2024)10.1016/j.ymthe.2024.09.034Source: DataRank Database

Engineered extracellular vesicles for combinatorial TNBC therapy: SR-SIM-guided design achieves substantial drug dosage reduction is a research paper published in Molecular Therapy (2024). On theSindex it has a DataRank of 0. It has been cited 13 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access13 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)OA: hybridTopics (38)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Kai Jin ORCID,Haizhu Shi,Austen Jones,Dalton Hironaka,Gaofeng Xiong

Live enrichment

PubMed:39369270 PMC:PMC11638871

National Institutes of Health

Grant: S10OD025008

National Cancer Institute

Grant: P30CA016058

National Cancer Institute

Grant: SCR_025078

National Cancer Institute

Grant: R01CA257961

National Cancer Institute

Grant: U01CA207946

NCI NIH HHS

Grant: R21 CA209045

NCI NIH HHS

Grant: R01 CA277946

NCI NIH HHS

Grant: R01 CA274981

hybridLicense: cc-by-nc-nd

publisherhttps://doi.org/10.1016/j.ymthe.2024.09.034

publisherhttps://api.elsevier.com/content/article/PII:S1525001624006580?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525001624006580?httpAccept=text/plain

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11638871/pdf/main.pdf

Fields of Study

Triple Negative Breast NeoplasmsAnimalsMiceExtracellular VesiclesHumansCell Line, TumorFemaleXenograft Model Antitumor AssaysRNA, Small InterferingSurvivinPaclitaxelGemcitabineDeoxycytidineAntineoplastic AgentsDrug Delivery SystemsDisease Models, Animal

MeSH Terms

Cell Line, TumorAnimalsHumansMiceDisease Models, AnimalPaclitaxelRNA, Small InterferingDeoxycytidineAntineoplastic AgentsDrug Delivery SystemsXenograft Model Antitumor AssaysFemaleTriple Negative Breast NeoplasmsExtracellular VesiclesSurvivinGemcitabine

Keywords

Cancer therapyCD44Extracellular VesiclesRna NanotechnologyTnbcSurvivin Sirna